Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FNTA | P49354 | 1/20 | 0.36 |
| ▸ | FNTB | P49356 | 1/20 | 0.36 |
| ▸ | KLKB1 | P03952 | 3/20 | 0.36 |
| ▸ | ELANE | P08246 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | AMPD2 | Q01433 | 6/20 | 0.35 |
| ▸ | CALCRL | Q16602 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | KLK1 | P06870 | 1/20 | 0.34 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.34 |
| ▸ | BACE1 | P56817 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6703343 | 1.00 | FNTA (0.36) | FNTAFNTBKLKB1ELANEALDH1A1 | |
| SCHEMBL6703342 | 1.00 | FNTA (0.36) | FNTAFNTBKLKB1ELANEALDH1A1 | |
| SCHEMBL6703355 | 0.85 | MDM2 (0.40) | FNTAFNTBSLC1A2 | |
| SCHEMBL6703358 | 0.85 | MDM2 (0.40) | FNTAFNTBSLC1A2 | |
| SCHEMBL6703359 | 0.85 | MDM2 (0.40) | FNTAFNTBSLC1A2 | |
| SCHEMBL6481273 | 0.80 | FNTA (0.43) | FNTAFNTBKLKB1ELANEALDH1A1 | |
| SCHEMBL6481278 | 0.80 | FNTA (0.43) | FNTAFNTBKLKB1ELANEALDH1A1 | |
| SCHEMBL6481276 | 0.80 | FNTA (0.43) | FNTAFNTBKLKB1ELANEALDH1A1 | |
| SCHEMBL6758465 | 0.79 | CALCRL (0.39) | ELANEALDH1A1AMPD2CALCRLCYP2C19 | |
| SCHEMBL4393271 | 0.79 | CALCRL (0.39) | ELANEALDH1A1AMPD2CALCRLCYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040220148-A1 | 5-Membered ring heterocycles as inhibitors of leucocyte adhesion and as VLA-4 antagonists | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-11-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040220148-A1 | 5-Membered ring heterocycles as inhibitors of leucocyte adhesion and as VLA-4 antagonists | VCAM1, LTB4R, ITGB4 | FNTA 1683/4885FNTB 1294/4885KLKB1 1865/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.